Longitudinal Analysis of Genitourinary and Bowel Symptoms in Prostate Cancer Patients Following Brachytherapy

Eckman, Mark H.; Jing, Ying; Hertzfeld, Kara; Kumar, Nitin; Barrett, William L.

doi:10.1097/coc.0b013e31819cd364

Cited by 6 publications

(3 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radical prostatectomy removes the obstruction and may relieve voiding LUTS in men with localised PrCa [5,6], while outcomes after transurethral prostatectomy in men with more extensive disease are less encouraging [7]. Radiation therapy decreases gland size and may relieve symptoms but can also exacerbate obstructive and irritative symptoms [8,9]. α-Blockers, 5α-reductase inhibitors and anticholinergics are used in the management of LUTS in patients with benign prostatic conditions [10] and also less commonly to alleviate symptoms in patients with PrCa undergoing radiotherapy [11].…”

Section: Introductionmentioning

confidence: 99%

Degarelix versus Goserelin (+ Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233)

et al. 2012

View full text Add to dashboard Cite

Introduction: No studies to date have assessed the efficacy/tolerability of degarelix in the relief of lower urinary tract symptoms (LUTS) secondary to prostate cancer (PrCa). Methods: Patients were randomised to degarelix 240/80 mg or goserelin 3.6 mg + bicalutamide flare protection (G+B); both treatments were administered for 3 months. The primary endpoint was change in International Prostate Symptom Score (IPSS) at week 12 compared with baseline. Results: This study was stopped early due to recruitment difficulties. 40 patients received treatment (degarelix n = 27; G+B n = 13); most had locally advanced disease and were highly symptomatic. Degarelix was non-inferior to G+B in reducing IPSS at week 12 in the full analysis set (p = 0.20); the significantly larger IPSS reduction in the per-protocol analysis (p = 0.04) was suggestive of superior reductions with degarelix. Significantly more degarelix patients had improved quality of life (IPSS question) at week 12 (85 vs. 46%; p = 0.01). Mean prostate size reductions at week 12 were 42 versus 25% for patients receiving degarelix versus G+B, respectively (p = 0.04; post hoc analysis). Most adverse events were mild/moderate; more degarelix patients experienced injection site reactions whereas more G+B patients had urinary tract infections/cystitis. Conclusion: In 40 men with predominantly locally advanced PrCa and highly symptomatic LUTS, degarelix was at least non-inferior to G+B in reducing IPSS at week 12.

show abstract

Section: Introductionmentioning

confidence: 99%

Degarelix versus Goserelin (+ Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233)

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Radioembolization remains continues to emerge as a promising locoregional therapy for primary and metastatic liver cancer [28]. While many patients respond favorably, progression of disease is observed in some patients.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Hepatic Tumor Response to Yttrium-90 Radioembolization Therapy Using Texture Signatures Generated from Contrast-enhanced CT Images

et al. 2012

View full text Add to dashboard Cite

Rationale and Objectives The aim of this study was to explore the use of texture features generated from liver computed tomographic (CT) datasets as potential image-based indicators of patient response to radioembolization (RE) with yttrium-90 (90Y) resin microspheres, an emerging locoregional therapy for advanced-stage liver cancer. Materials and Methods Overall post-therapy survival and percent change in serologic tumor marker at three months post-therapy represent the primary clinical outcomes in this study. Thirty advanced-stage liver cancer cases (primary and metastatic) treated with RE over a three year period were included. Texture signatures for tumor regions, which were delineated to reveal boundaries with normal regions, were computed from pre-treatment contrast-enhanced liver CT studies and evaluated for their ability to classify patient serologic response and survival. Results A series of systematic leave-one-out cross-validation studies using soft-margin support vector machine (SVM) classifiers showed hepatic tumor texton and local binary pattern (LBP) signatures both achieve high accuracy (96%) in discriminating subjects in terms of their serologic response. The image-based indicators were also accurate in classifying subjects by survival status (80% and 93% accuracy for texton and LBP signatures, respectively). Conclusions Hepatic texture signatures generated from tumor regions on pre-treatment triphasic CT studies were highly accurate in differentiating among subjects in terms of serologic response and survival. These image-based computational markers show promise as potential predictive tools in candidate evaluation for locoregional therapy such as RE.

show abstract

“…Some studies show no detectable increased risk of prostate cancer in transplant patients. 22,23 Multiple decision aids have been developed to inform and assist the patient in the decision regarding which treatment to pursue. [13][14][15][16][17][18][19] Prostate cancer is a unique malignancy in that there are several management options for localized cancer.…”

mentioning

confidence: 99%

Outcomes in Transplant Patients Undergoing Brachytherapy for Prostate Cancer

Coombs

Hertzfeld

Barrett

2012

American Journal of Clinical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Longitudinal Analysis of Genitourinary and Bowel Symptoms in Prostate Cancer Patients Following Brachytherapy

Cited by 6 publications

References 75 publications

Degarelix versus Goserelin (+ Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233)

Degarelix versus Goserelin (+ Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233)

Evaluation of Hepatic Tumor Response to Yttrium-90 Radioembolization Therapy Using Texture Signatures Generated from Contrast-enhanced CT Images

Outcomes in Transplant Patients Undergoing Brachytherapy for Prostate Cancer

Contact Info

Product

Resources

About